|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q40617416
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010719.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q40617416
|
|
024
|
|
|
‡a
0000-0002-5592-6199
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q40617416
|
|
100
|
0 |
|
‡a
Jorge Ferreira
‡c
researcher (ORCID 0000-0002-5592-6199)
‡9
en
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
Jorge Ferreira
‡c
onderzoeker
‡9
nl
|
|
670
|
|
|
‡a
Author's [@HOME is a new Eu-Project in Tele Home care]
|
|
670
|
|
|
‡a
Author's Acute myocardial infarction complicated by cardiogenic shock: what changed over a 10-year time span?
|
|
670
|
|
|
‡a
Author's Anemia and iron deficiency in heart failure.
|
|
670
|
|
|
‡a
Author's Apical ballooning syndrome during diagnostic coronary angiography
|
|
670
|
|
|
‡a
Author's Applicability of the Zwolle risk score for safe early discharge after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction
|
|
670
|
|
|
‡a
Author's Assessment of perioperative mortality risk in patients with infective endocarditis undergoing cardiac surgery: performance of the EuroSCORE I and II logistic models.
|
|
670
|
|
|
‡a
Author's Cardiac mass in a patient with chronic lymphocytic leukemia
|
|
670
|
|
|
‡a
Author's Cardiovascular risk associated with interruption of antiplatelet and oral anticoagulation therapy.
|
|
670
|
|
|
‡a
Author's Cholesterol is Inefficiently Converted to Cholesteryl Esters in the Blood of Cardiovascular Disease Patients
|
|
670
|
|
|
‡a
Author's Cholesterol pericarditis--relapsing pericardial effusion in a patient with rheumatoid arthritis.
|
|
670
|
|
|
‡a
Author's [Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation].
|
|
670
|
|
|
‡a
Author's Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
|
|
670
|
|
|
‡a
Author's Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
|
|
670
|
|
|
‡a
Author's Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry
|
|
670
|
|
|
‡a
Author's Compliance of pharmacological treatment for non-ST-elevation acute coronary syndromes with contemporary guidelines: influence on outcomes
|
|
670
|
|
|
‡a
Author's Coronary sinus pacing in a patient with a tricuspid prosthesis.
|
|
670
|
|
|
‡a
Author's Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial
|
|
670
|
|
|
‡a
Author's Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions
|
|
670
|
|
|
‡a
Author's Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists
|
|
670
|
|
|
‡a
Author's Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report.
|
|
670
|
|
|
‡a
Author's Diagnosis of myocardial infarction using the new universal definition: is it enough for risk stratification and guiding decision for revascularization?
|
|
670
|
|
|
‡a
Author's Early reperfusion in myocardial infarction requires widespread access to prehospital emergency care
|
|
670
|
|
|
‡a
Author's Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation
|
|
670
|
|
|
‡a
Author's [Effectiveness and safety of coronary vasodilation with adenosine triphosphate with thallium-201 for the diagnosis of coronary disease]
|
|
670
|
|
|
‡a
Author's [Elective coronary angioplasty in acute coronary syndromes: early versus delayed treatment]
|
|
670
|
|
|
‡a
Author's For the improvement of Heart Failure treatment in Portugal - Consensus statement.
|
|
670
|
|
|
‡a
Author's Fusion of risk assessment models with application to coronary artery disease patients
|
|
670
|
|
|
‡a
Author's Glucose metabolism in non-diabetic patients with stable coronary artery disease.
|
|
670
|
|
|
‡a
Author's [Holter electrocardiography en pediatric cardiology: preliminary experience]
|
|
670
|
|
|
‡a
Author's Identifying predictors of patient delay for reperfusion in myocardial infarction: Does it matter?
|
|
670
|
|
|
‡a
Author's Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years
|
|
670
|
|
|
‡a
Author's Implantable Cardioverter-Defibrillators in Trials of Drug Therapy for Heart Failure: A Systematic Review and Meta-Analysis
|
|
670
|
|
|
‡a
Author's Improvement of CVD risk assessment tools' performance through innovative patients' grouping strategies
|
|
670
|
|
|
‡a
Author's Infectious endocarditis caused by Q fever. Apropos of a clinical case
|
|
670
|
|
|
‡a
Author's Influence of prior medication on mode of presentation and prognosis of acute coronary syndromes
|
|
670
|
|
|
‡a
Author's Integration of Different Risk Assessment Tools to Improve Stratification of Patients with Coronary Artery Disease
|
|
670
|
|
|
‡a
Author's Invasive strategy should be considered for all people with unstable angina or non-ST segment elevation myocardial infarction. Commentary
|
|
670
|
|
|
‡a
Author's [Long-term use of a left ventricular assist device for end-stage heart failure]
|
|
670
|
|
|
‡a
Author's Metabolic score--a simple risk marker in non-ST elevation acute coronary syndromes
|
|
670
|
|
|
‡a
Author's [Myocardial infarction in patients with single-vessel disease: are there clinical or angiographic markers of viability?]
|
|
670
|
|
|
‡a
Author's Myocardial infarction without obstructive coronary disease complicated by ventricular septal rupture
|
|
670
|
|
|
‡a
Author's National Registry of Acute Coronary Syndromes: results of the hospital phase in 2002.
|
|
670
|
|
|
‡a
Author's New approaches for improving cardiovascular risk assessment.
|
|
670
|
|
|
‡a
Author's No fate but what we make: a case of full recovery after out-of-hospital cardiac arrest
|
|
670
|
|
|
‡a
Author's Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials.
|
|
670
|
|
|
‡a
Author's Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
|
|
670
|
|
|
‡a
Author's Portuguese registries of acute coronary syndromes - Opportunities for improvement
|
|
670
|
|
|
‡a
Author's Practical guide for the use of PCSK9 inhibitors in Portugal
|
|
670
|
|
|
‡a
Author's Prognosis in patients with left bundle branch block and normal dipyridamole thallium-201 scintigraphy
|
|
670
|
|
|
‡a
Author's Prognosis of non-ST-segment elevation acute coronary syndrome in patients with prior percutaneous coronary intervention
|
|
670
|
|
|
‡a
Author's Prognostic value of cardiac troponin I release kinetics in unstable angina
|
|
670
|
|
|
‡a
Author's Prognostic value of continuous ST-segment monitoring in patients with non-ST-segment elevation acute coronary syndromes
|
|
670
|
|
|
‡a
Author's Prognostic value of electrocardiogram exercise testing for risk stratification in asymptomatic coronary artery disease
|
|
670
|
|
|
‡a
Author's Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials.
|
|
670
|
|
|
‡a
Author's Reduction of thrombogenic potential by physical exercise in the elderly
|
|
670
|
|
|
‡a
Author's Relationship between radionuclide right ventricular ejection fraction and clinical status in patients with left ventricular dysfunction after myocardial infarction
|
|
670
|
|
|
‡a
Author's [Response of the left ventricular ejection fraction,assessed by by radionuclide angiography, to inotropic stimulation: its relationship with the reversibility of perfusion defects in thallium-201 scintigraphy with overload-reinjection protocol]
|
|
670
|
|
|
‡a
Author's Revascularization and prognosis in female patients with non-ST-segment elevation acute coronary syndromes
|
|
670
|
|
|
‡a
Author's [Reversibility in perfusion scintigraphy after myocardial infarct: a comparison between the protocol of single-day rest-stress with 99mTc sestamibi and reinjection with thallium-201]
|
|
670
|
|
|
‡a
Author's Risk stratification in acute coronary syndromes: When less is more
|
|
670
|
|
|
‡a
Author's Risk stratification in normotensive acute pulmonary embolism patients: focus on the intermediate-high risk subgroup
|
|
670
|
|
|
‡a
Author's Sacubitril/valsartan: A practical guide
|
|
670
|
|
|
‡a
Author's Sacubitril/valsartan: A practical guide revisited
|
|
670
|
|
|
‡a
Author's Serologic markers for cytomegalovirus in acute coronary syndromes.
|
|
670
|
|
|
‡a
Author's Shotgun mass spectrometry-based lipid profiling identifies and distinguishes between chronic inflammatory diseases
|
|
670
|
|
|
‡a
Author's Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
|
|
670
|
|
|
‡a
Author's [Stress echocardiography with dipyridamole/atropine in the detection of myocardial ischemia: a comparison with thallium-201 scintigraphy and an angiographic correlation]
|
|
670
|
|
|
‡a
Author's [Superiority of the reinjection method compared with the redistribution of thallium-201 in the evaluation of reversibility after myocardial infarction]
|
|
670
|
|
|
‡a
Author's T wave positivity in resting electrocardiogram predicts preserved systolic thickening in chronic anterior Q wave myocardial infarction: an echocardiographic study
|
|
670
|
|
|
‡a
Author's [The 3-year prognosis of patients with suspected coronary disease and a normal myocardial scintigraphy with thallium-dipyridamole]
|
|
670
|
|
|
‡a
Author's [The analysis of negative studies in myocardial perfusion scintigraphy]
|
|
670
|
|
|
‡a
Author's [The evolution of the arterial pressure during a stress test in patients with hypertrophic myocardiopathy]
|
|
670
|
|
|
‡a
Author's The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
|
|
670
|
|
|
‡a
Author's [The prognostic significance of late potentials in patients with chronic coronary disease]
|
|
670
|
|
|
‡a
Author's [The radiofrequency catheter ablation of occult accessory atrioventricular pathways]
|
|
670
|
|
|
‡a
Author's [The role of abciximab in the prevention of the acute thrombotic complications of coronary angioplasty]
|
|
670
|
|
|
‡a
Author's The ups and downs of the electrocardiogram for identification of the infarct-related artery
|
|
670
|
|
|
‡a
Author's TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS.
|
|
670
|
|
|
‡a
Author's To be or not to be referred for cardiac rehabilitation after acute coronary syndrome
|
|
670
|
|
|
‡a
Author's Vascular phenotypes of acute decompensated vs. new-onset heart failure: treatment implications
|
|
909
|
|
|
‡a
(orcid) 0000000255926199
‡9
1
|
|
919
|
|
|
‡a
riskstratificationinacutecoronarysyndromeswhenlessismore
‡A
Risk stratification in acute coronary syndromes: When less is more
‡9
1
|
|
919
|
|
|
‡a
reversibilityinperfusionscintigraphyaftermyocardialinfarctacomparisonbetweentheprotocolofsingledayreststresswith99mtcsestamibiandreinjectionwiththallium201
‡A
[Reversibility in perfusion scintigraphy after myocardial infarct: a comparison between the protocol of single-day rest-stress with 99mTc sestamibi and reinjection with thallium-201]
‡9
1
|
|
919
|
|
|
‡a
revascularizationandprognosisinfemalepatientswithnonstsegmentelevationacutecoronarysyndromes
‡A
Revascularization and prognosis in female patients with non-ST-segment elevation acute coronary syndromes
‡9
1
|
|
919
|
|
|
‡a
responseoftheleftventricularejectionfractionassessedbybyradionuclideangiographytoinotropicstimulationitsrelationshipwiththereversibilityofperfusiondefectsinthallium201scintigraphywithoverloadreinjectionprotocol
‡A
[Response of the left ventricular ejection fraction,assessed by by radionuclide angiography, to inotropic stimulation: its relationship with the reversibility of perfusion defects in thallium-201 scintigraphy with overload-reinjection protocol]
‡9
1
|
|
919
|
|
|
‡a
relationshipbetweenradionucliderightventricularejectionfractionandclinicalstatusinpatientswithleftventriculardysfunctionaftermyocardialinfarction
‡A
Relationship between radionuclide right ventricular ejection fraction and clinical status in patients with left ventricular dysfunction after myocardial infarction
‡9
1
|
|
919
|
|
|
‡a
reductionofthrombogenicpotentialbyphysicalexerciseintheelderly
‡A
Reduction of thrombogenic potential by physical exercise in the elderly
‡9
1
|
|
919
|
|
|
‡a
pulmonaryarterycatheterizationinacutecoronarysyndromesinsightsfromthegustoiibandgusto3trials
‡A
Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials.
‡9
1
|
|
919
|
|
|
‡a
prognosticvalueofelectrocardiogramexercisetestingforriskstratificationinasymptomaticcoronaryarterydisease
‡A
Prognostic value of electrocardiogram exercise testing for risk stratification in asymptomatic coronary artery disease
‡9
1
|
|
919
|
|
|
‡a
prognosticvalueofcontinuousstsegmentmonitoringinpatientswithnonstsegmentelevationacutecoronarysyndromes
‡A
Prognostic value of continuous ST-segment monitoring in patients with non-ST-segment elevation acute coronary syndromes
‡9
1
|
|
919
|
|
|
‡a
prognosticvalueofcardiactroponin1releasekineticsinunstableangina
‡A
Prognostic value of cardiac troponin I release kinetics in unstable angina
‡9
1
|
|
919
|
|
|
‡a
prognosisofnonstsegmentelevationacutecoronarysyndromeinpatientswithpriorpercutaneouscoronaryintervention
‡A
Prognosis of non-ST-segment elevation acute coronary syndrome in patients with prior percutaneous coronary intervention
‡9
1
|
|
919
|
|
|
‡a
prognosisinpatientswithleftbundlebranchblockandnormaldipyridamolethallium201scintigraphy
‡A
Prognosis in patients with left bundle branch block and normal dipyridamole thallium-201 scintigraphy
‡9
1
|
|
919
|
|
|
‡a
practicalguidefortheuseofpcsk9inhibitorsinportugal
‡A
Practical guide for the use of PCSK9 inhibitors in Portugal
‡9
1
|
|
919
|
|
|
‡a
portugueseregistriesofacutecoronarysyndromesopportunitiesforimprovement
‡A
Portuguese registries of acute coronary syndromes - Opportunities for improvement
‡9
1
|
|
919
|
|
|
‡a
patientoutcomesusingtheeuropeanlabelfordabigatranaposthocanalysisfromtherelydatabase
‡A
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
‡9
1
|
|
919
|
|
|
‡a
nonvitaminkantagonistoralanticoagulantscomparedwithwarfarinatdifferentlevelsofinrcontrolinatrialfibrillationametaanalysisofrandomizedtrials
‡A
Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials.
‡9
1
|
|
919
|
|
|
‡a
nofatebutwhatwemakeacaseoffullrecoveryafteroutofhospitalcardiacarrest
‡A
No fate but what we make: a case of full recovery after out-of-hospital cardiac arrest
‡9
1
|
|
919
|
|
|
‡a
newapproachesforimprovingcardiovascularriskassessment
‡A
New approaches for improving cardiovascular risk assessment.
‡9
1
|
|
919
|
|
|
‡a
nationalregistryofacutecoronarysyndromesresultsofthehospitalphasein
‡A
National Registry of Acute Coronary Syndromes: results of the hospital phase in 2002.
‡9
1
|
|
919
|
|
|
‡a
myocardialinfarctionwithoutobstructivecoronarydiseasecomplicatedbyventricularseptalrupture
‡A
Myocardial infarction without obstructive coronary disease complicated by ventricular septal rupture
‡9
1
|
|
919
|
|
|
‡a
myocardialinfarctioninpatientswithsinglevesseldiseasearethereclinicalorangiographicmarkersofviability
‡A
[Myocardial infarction in patients with single-vessel disease: are there clinical or angiographic markers of viability?]
‡9
1
|
|
919
|
|
|
‡a
metabolicscoreasimpleriskmarkerinnonstelevationacutecoronarysyndromes
‡A
Metabolic score--a simple risk marker in non-ST elevation acute coronary syndromes
‡9
1
|
|
919
|
|
|
‡a
longtermuseofaleftventricularassistdeviceforendstageheartfailure
‡A
[Long-term use of a left ventricular assist device for end-stage heart failure]
‡9
1
|
|
919
|
|
|
‡a
invasivestrategyshouldbeconsideredforallpeoplewithunstableanginaornonstsegmentelevationmyocardialinfarctioncommentary
‡A
Invasive strategy should be considered for all people with unstable angina or non-ST segment elevation myocardial infarction. Commentary
‡9
1
|
|
919
|
|
|
‡a
integrationofdifferentriskassessmenttoolstoimprovestratificationofpatientswithcoronaryarterydisease
‡A
Integration of Different Risk Assessment Tools to Improve Stratification of Patients with Coronary Artery Disease
‡9
1
|
|
919
|
|
|
‡a
influenceofpriormedicationonmodeofpresentationandprognosisofacutecoronarysyndromes
‡A
Influence of prior medication on mode of presentation and prognosis of acute coronary syndromes
‡9
1
|
|
919
|
|
|
‡a
infectiousendocarditiscausedbyqfeveraproposofaclinicalcase
‡A
Infectious endocarditis caused by Q fever. Apropos of a clinical case
‡9
1
|
|
919
|
|
|
‡a
improvementofcvdriskassessmenttoolsperformancethroughinnovativepatientsgroupingstrategies
‡A
Improvement of CVD risk assessment tools' performance through innovative patients' grouping strategies
‡9
1
|
|
919
|
|
|
‡a
implantablecardioverterdefibrillatorsintrialsofdrugtherapyforheartfailureasystematicreviewandmetaanalysis
‡A
Implantable Cardioverter-Defibrillators in Trials of Drug Therapy for Heart Failure: A Systematic Review and Meta-Analysis
‡9
1
|
|
919
|
|
|
‡a
impactofescaccfahawhfuniversaldefinitionofmyocardialinfarctiononmortalityat10years
‡A
Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years
‡9
1
|
|
919
|
|
|
‡a
identifyingpredictorsofpatientdelayforreperfusioninmyocardialinfarctiondoesitmatter
‡A
Identifying predictors of patient delay for reperfusion in myocardial infarction: Does it matter?
‡9
1
|
|
919
|
|
|
‡a
holterelectrocardiographyenpediatriccardiologypreliminaryexperience
‡A
[Holter electrocardiography en pediatric cardiology: preliminary experience]
‡9
1
|
|
919
|
|
|
‡a
glucosemetabolisminnondiabeticpatientswithstablecoronaryarterydisease
‡A
Glucose metabolism in non-diabetic patients with stable coronary artery disease.
‡9
1
|
|
919
|
|
|
‡a
fusionofriskassessmentmodelswithapplicationtocoronaryarterydiseasepatients
‡A
Fusion of risk assessment models with application to coronary artery disease patients
‡9
1
|
|
919
|
|
|
‡a
fortheimprovementofheartfailuretreatmentinportugalconsensusstatement
‡A
For the improvement of Heart Failure treatment in Portugal - Consensus statement.
‡9
1
|
|
919
|
|
|
‡a
electivecoronaryangioplastyinacutecoronarysyndromesearlyversusdelayedtreatment
‡A
[Elective coronary angioplasty in acute coronary syndromes: early versus delayed treatment]
‡9
1
|
|
919
|
|
|
‡a
effectivenessandsafetyofcoronaryvasodilationwithadenosinetriphosphatewiththallium201forthediagnosisofcoronarydisease
‡A
[Effectiveness and safety of coronary vasodilation with adenosine triphosphate with thallium-201 for the diagnosis of coronary disease]
‡9
1
|
|
919
|
|
|
‡a
economicevaluationofdabigatranforstrokepreventioninpatientswithnonvalvularatrialfibrillation
‡A
Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation
‡9
1
|
|
919
|
|
|
‡a
earlyreperfusioninmyocardialinfarctionrequireswidespreadaccesstoprehospitalemergencycare
‡A
Early reperfusion in myocardial infarction requires widespread access to prehospital emergency care
‡9
1
|
|
919
|
|
|
‡a
diagnosisofmyocardialinfarctionusingthenewuniversaldefinitionisitenoughforriskstratificationandguidingdecisionforrevascularization
‡A
Diagnosis of myocardial infarction using the new universal definition: is it enough for risk stratification and guiding decision for revascularization?
‡9
1
|
|
919
|
|
|
‡a
dabigatranreversalwithidarucizumabinapatientundergoinghearttransplantation1europeanreport
‡A
Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report.
‡9
1
|
|
919
|
|
|
‡a
dabigatraninrealworldatrialfibrillationmetaanalysisofobservationalcomparisonstudieswithvitaminkantagonists
‡A
Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists
‡9
1
|
|
919
|
|
|
‡a
dabigatranforstrokepreventioninnonvalvularatrialfibrillationanswerstochallengingrealworldquestions
‡A
Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions
‡9
1
|
|
919
|
|
|
‡a
dabigatrancomparedwithwarfarininpatientswithatrialfibrillationandsymptomaticheartfailureasubgroupanalysisoftherelytrial
‡A
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial
‡9
1
|
|
919
|
|
|
‡a
coronarysinuspacinginapatientwithatricuspidprosthesis
‡A
Coronary sinus pacing in a patient with a tricuspid prosthesis.
‡9
1
|
|
919
|
|
|
‡a
complianceofpharmacologicaltreatmentfornonstelevationacutecoronarysyndromeswithcontemporaryguidelinesinfluenceonoutcomes
‡A
Compliance of pharmacological treatment for non-ST-elevation acute coronary syndromes with contemporary guidelines: influence on outcomes
‡9
1
|
|
919
|
|
|
‡a
complementaryeffectsofsirolimuselutingstentsandglycoproteiniibiiiainhibitorsforpercutaneouscoronaryinterventionindiabeticpatients1yearfollowupofasinglecentreregistry
‡A
Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry
‡9
1
|
|
919
|
|
|
‡a
clinicalefficacyandsafetyofevolocumabinhighriskpatientsreceivingastatinsecondaryanalysisofpatientswithlowldlcholesterollevelsandinthosealreadyreceivingamaximalpotencystatininarandomizedclinicaltrial
‡A
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
‡9
1
|
|
919
|
|
|
‡a
clinicalbenefitofevolocumabbyseverityandextentofcoronaryarterydiseaseanalysisfromfourier
‡A
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
‡9
1
|
|
919
|
|
|
‡a
clinicalandeconomicconsequencesofusingdabigatranorrivaroxabaninpatientswithnonvalvularatrialfibrillation
‡A
[Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation].
‡9
1
|
|
919
|
|
|
‡a
cholesterolpericarditisrelapsingpericardialeffusioninapatientwithrheumatoidarthritis
‡A
Cholesterol pericarditis--relapsing pericardial effusion in a patient with rheumatoid arthritis.
‡9
1
|
|
919
|
|
|
‡a
cholesterolisinefficientlyconvertedtocholesterylestersinthebloodofcardiovasculardiseasepatients
‡A
Cholesterol is Inefficiently Converted to Cholesteryl Esters in the Blood of Cardiovascular Disease Patients
‡9
1
|
|
919
|
|
|
‡a
cardiovascularriskassociatedwithinterruptionofantiplateletandoralanticoagulationtherapy
‡A
Cardiovascular risk associated with interruption of antiplatelet and oral anticoagulation therapy.
‡9
1
|
|
919
|
|
|
‡a
cardiacmassinapatientwithchroniclymphocyticleukemia
‡A
Cardiac mass in a patient with chronic lymphocytic leukemia
‡9
1
|
|
919
|
|
|
‡a
assessmentofperioperativemortalityriskinpatientswithinfectiveendocarditisundergoingcardiacsurgeryperformanceoftheeuroscore1and2logisticmodels
‡A
Assessment of perioperative mortality risk in patients with infective endocarditis undergoing cardiac surgery: performance of the EuroSCORE I and II logistic models.
‡9
1
|
|
919
|
|
|
‡a
applicabilityofthezwolleriskscoreforsafeearlydischargeafterprimarypercutaneouscoronaryinterventioninstsegmentelevationmyocardialinfarction
‡A
Applicability of the Zwolle risk score for safe early discharge after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction
‡9
1
|
|
919
|
|
|
‡a
apicalballooningsyndromeduringdiagnosticcoronaryangiography
‡A
Apical ballooning syndrome during diagnostic coronary angiography
‡9
1
|
|
919
|
|
|
‡a
anemiaandirondeficiencyinheartfailure
‡A
Anemia and iron deficiency in heart failure.
‡9
1
|
|
919
|
|
|
‡a
acutemyocardialinfarctioncomplicatedbycardiogenicshockwhatchangedovera10yeartimespan
‡A
Acute myocardial infarction complicated by cardiogenic shock: what changed over a 10-year time span?
‡9
1
|
|
919
|
|
|
‡a
@homeisaneweuprojectintelehomecare
‡A
[@HOME is a new Eu-Project in Tele Home care]
‡9
1
|
|
919
|
|
|
‡a
upsanddownsoftheelectrocardiogramforidentificationoftheinfarctrelatedartery
‡A
The ups and downs of the electrocardiogram for identification of the infarct-related artery
‡9
1
|
|
919
|
|
|
‡a
sodiumglucosecotransporter2inhibitorsinthefailingheartagrowingpotential
‡A
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
‡9
1
|
|
919
|
|
|
‡a
stressechocardiographywithdipyridamoleatropineinthedetectionofmyocardialischemiaacomparisonwiththallium201scintigraphyandanangiographiccorrelation
‡A
[Stress echocardiography with dipyridamole/atropine in the detection of myocardial ischemia: a comparison with thallium-201 scintigraphy and an angiographic correlation]
‡9
1
|
|
919
|
|
|
‡a
superiorityofthereinjectionmethodcomparedwiththeredistributionofthallium201intheevaluationofreversibilityaftermyocardialinfarction
‡A
[Superiority of the reinjection method compared with the redistribution of thallium-201 in the evaluation of reversibility after myocardial infarction]
‡9
1
|
|
919
|
|
|
‡a
twavepositivityinrestingelectrocardiogrampredictspreservedsystolicthickeninginchronicanteriorqwavemyocardialinfarctionanechocardiographicstudy
‡A
T wave positivity in resting electrocardiogram predicts preserved systolic thickening in chronic anterior Q wave myocardial infarction: an echocardiographic study
‡9
1
|
|
919
|
|
|
‡a
3yearprognosisofpatientswithsuspectedcoronarydiseaseandanormalmyocardialscintigraphywiththalliumdipyridamole
‡A
[The 3-year prognosis of patients with suspected coronary disease and a normal myocardial scintigraphy with thallium-dipyridamole]
‡9
1
|
|
919
|
|
|
‡a
analysisofnegativestudiesinmyocardialperfusionscintigraphy
‡A
[The analysis of negative studies in myocardial perfusion scintigraphy]
‡9
1
|
|
919
|
|
|
‡a
evolutionofthearterialpressureduringastresstestinpatientswithhypertrophicmyocardiopathy
‡A
[The evolution of the arterial pressure during a stress test in patients with hypertrophic myocardiopathy]
‡9
1
|
|
919
|
|
|
‡a
longtermmulticenterobservationalstudyofdabigatrantreatmentinpatientswithatrialfibrillationrelyablestudy
‡A
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
‡9
1
|
|
919
|
|
|
‡a
prognosticsignificanceoflatepotentialsinpatientswithchroniccoronarydisease
‡A
[The prognostic significance of late potentials in patients with chronic coronary disease]
‡9
1
|
|
919
|
|
|
‡a
radiofrequencycatheterablationofoccultaccessoryatrioventricularpathways
‡A
[The radiofrequency catheter ablation of occult accessory atrioventricular pathways]
‡9
1
|
|
919
|
|
|
‡a
roleofabciximabinthepreventionoftheacutethromboticcomplicationsofcoronaryangioplasty
‡A
[The role of abciximab in the prevention of the acute thrombotic complications of coronary angioplasty]
‡9
1
|
|
919
|
|
|
‡a
timipursuitandgraceriskscoressustainedprognosticvalueandinteractionwithrevascularizationinnsteacs
‡A
TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS.
‡9
1
|
|
919
|
|
|
‡a
tobeornottobereferredforcardiacrehabilitationafteracutecoronarysyndrome
‡A
To be or not to be referred for cardiac rehabilitation after acute coronary syndrome
‡9
1
|
|
919
|
|
|
‡a
vascularphenotypesofacutedecompensatedvsnewonsetheartfailuretreatmentimplications
‡A
Vascular phenotypes of acute decompensated vs. new-onset heart failure: treatment implications
‡9
1
|
|
919
|
|
|
‡a
shotgunmassspectrometrybasedlipidprofilingidentifiesanddistinguishesbetweenchronicinflammatorydiseases
‡A
Shotgun mass spectrometry-based lipid profiling identifies and distinguishes between chronic inflammatory diseases
‡9
1
|
|
919
|
|
|
‡a
serologicmarkersforcytomegalovirusinacutecoronarysyndromes
‡A
Serologic markers for cytomegalovirus in acute coronary syndromes.
‡9
1
|
|
919
|
|
|
‡a
sacubitrilvalsartanapracticalguiderevisited
‡A
Sacubitril/valsartan: A practical guide revisited
‡9
1
|
|
919
|
|
|
‡a
sacubitrilvalsartanapracticalguide
‡A
Sacubitril/valsartan: A practical guide
‡9
1
|
|
919
|
|
|
‡a
riskstratificationinnormotensiveacutepulmonaryembolismpatientsfocusontheintermediatehighrisksubgroup
‡A
Risk stratification in normotensive acute pulmonary embolism patients: focus on the intermediate-high risk subgroup
‡9
1
|
|
943
|
|
|
‡a
200x
‡A
2002
‡9
1
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
SUDOC|27386338X
|
|
996
|
|
|
‡2
ISNI|0000000069113944
|
|
996
|
|
|
‡2
SUDOC|182113221
|
|
996
|
|
|
‡2
BLBNB|001578298
|
|
996
|
|
|
‡2
ISNI|0000000068923718
|
|
996
|
|
|
‡2
ISNI|000000006798093X
|
|
996
|
|
|
‡2
PTBNP|1427936
|
|
996
|
|
|
‡2
PTBNP|1674181
|
|
996
|
|
|
‡2
PTBNP|799585
|
|
996
|
|
|
‡2
BLBNB|001474414
|
|
996
|
|
|
‡2
DNB|1056541814
|
|
996
|
|
|
‡2
PTBNP|964999
|
|
996
|
|
|
‡2
LC|n 88157702
|
|
996
|
|
|
‡2
PTBNP|1872577
|
|
996
|
|
|
‡2
LC|no2001048113
|
|
996
|
|
|
‡2
PTBNP|230041
|
|
996
|
|
|
‡2
SUDOC|153140631
|
|
996
|
|
|
‡2
SUDOC|08822029X
|
|
996
|
|
|
‡2
LC|nb2003110655
|
|
996
|
|
|
‡2
ISNI|0000000067987170
|
|
996
|
|
|
‡2
ISNI|000000038406816X
|
|
996
|
|
|
‡2
PTBNP|1034965
|
|
996
|
|
|
‡2
PTBNP|32224
|
|
996
|
|
|
‡2
NTA|241801532
|
|
996
|
|
|
‡2
PTBNP|1098981
|
|
996
|
|
|
‡2
BLBNB|000328454
|
|
996
|
|
|
‡2
BLBNB|000608069
|
|
996
|
|
|
‡2
RERO|A022542006
|
|
996
|
|
|
‡2
BLBNB|000203469
|
|
996
|
|
|
‡2
BLBNB|000203468
|
|
996
|
|
|
‡2
ISNI|000000041937386X
|
|
996
|
|
|
‡2
RERO|A013475289
|
|
996
|
|
|
‡2
ISNI|0000000428255558
|
|
996
|
|
|
‡2
ISNI|000000007011053X
|
|
996
|
|
|
‡2
BLBNB|000462005
|
|
996
|
|
|
‡2
NTA|068654006
|
|
996
|
|
|
‡2
SUDOC|260491349
|
|
996
|
|
|
‡2
PTBNP|1879956
|
|
996
|
|
|
‡2
LC|nb2017002071
|
|
996
|
|
|
‡2
PTBNP|1480009
|
|
996
|
|
|
‡2
J9U|987007360393405171
|
|
996
|
|
|
‡2
PTBNP|1343146
|
|
996
|
|
|
‡2
SUDOC|126281416
|
|
996
|
|
|
‡2
ISNI|0000000078818380
|
|
996
|
|
|
‡2
BNF|18103591
|
|
996
|
|
|
‡2
PLWABN|9814008311005606
|
|
996
|
|
|
‡2
SUDOC|149481608
|
|
996
|
|
|
‡2
DNB|1230413626
|
|
996
|
|
|
‡2
PTBNP|904940
|
|
996
|
|
|
‡2
ISNI|0000000428296245
|
|
996
|
|
|
‡2
PTBNP|1897881
|
|
996
|
|
|
‡2
BLBNB|000580329
|
|
996
|
|
|
‡2
PTBNP|278068
|
|
996
|
|
|
‡2
ISNI|0000000068117978
|
|
996
|
|
|
‡2
NTA|097002291
|
|
996
|
|
|
‡2
ISNI|0000000070034872
|
|
996
|
|
|
‡2
PTBNP|1361774
|
|
996
|
|
|
‡2
PTBNP|335994
|
|
996
|
|
|
‡2
PTBNP|191357
|
|
996
|
|
|
‡2
BNF|14177056
|
|
996
|
|
|
‡2
BNF|17999833
|
|
996
|
|
|
‡2
BLBNB|000203471
|
|
996
|
|
|
‡2
LC|no2004068732
|
|
996
|
|
|
‡2
DNB|1181001617
|
|
996
|
|
|
‡2
DNB|1053250223
|
|
996
|
|
|
‡2
PTBNP|286969
|
|
996
|
|
|
‡2
PTBNP|1544619
|
|
996
|
|
|
‡2
ISNI|0000000044702590
|
|
996
|
|
|
‡2
PTBNP|1467189
|
|
996
|
|
|
‡2
DNB|1073735753
|
|
996
|
|
|
‡2
PTBNP|286765
|
|
996
|
|
|
‡2
DNB|1036491129
|
|
996
|
|
|
‡2
LC|nb2013016368
|
|
996
|
|
|
‡2
PTBNP|34968
|
|
996
|
|
|
‡2
DNB|1057433519
|
|
996
|
|
|
‡2
ISNI|0000000084535555
|
|
996
|
|
|
‡2
PTBNP|1911872
|
|
996
|
|
|
‡2
PTBNP|1478589
|
|
996
|
|
|
‡2
BLBNB|001028709
|
|
996
|
|
|
‡2
DNB|1057347159
|
|
996
|
|
|
‡2
SUDOC|14493762X
|
|
996
|
|
|
‡2
DNB|1047922703
|
|
996
|
|
|
‡2
ISNI|0000000068898890
|
|
996
|
|
|
‡2
BLBNB|001541776
|
|
996
|
|
|
‡2
RERO|A000062310
|
|
996
|
|
|
‡2
PTBNP|88081
|
|
996
|
|
|
‡2
LC|no2009168124
|
|
996
|
|
|
‡2
ISNI|0000000036812116
|
|
996
|
|
|
‡2
PTBNP|1751724
|
|
996
|
|
|
‡2
PTBNP|1450668
|
|
996
|
|
|
‡2
PTBNP|1919159
|
|
996
|
|
|
‡2
DNB|1240334958
|
|
996
|
|
|
‡2
NTA|228019451
|
|
996
|
|
|
‡2
PTBNP|272264
|
|
996
|
|
|
‡2
PTBNP|1651037
|
|
996
|
|
|
‡2
LC|no 95025762
|
|
996
|
|
|
‡2
ISNI|0000000068107737
|
|
996
|
|
|
‡2
DNB|1056528893
|
|
996
|
|
|
‡2
PTBNP|1408151
|
|
996
|
|
|
‡2
PTBNP|1212164
|
|
996
|
|
|
‡2
PTBNP|138864
|
|
996
|
|
|
‡2
ARBABN|000039386
|
|
996
|
|
|
‡2
PTBNP|1797679
|
|
996
|
|
|
‡2
PTBNP|110706
|
|
996
|
|
|
‡2
LC|no2019156105
|
|
996
|
|
|
‡2
LC|no2017016039
|
|
996
|
|
|
‡2
PTBNP|54573
|
|
996
|
|
|
‡2
PTBNP|1656368
|
|
996
|
|
|
‡2
BNF|14605720
|
|
996
|
|
|
‡2
ISNI|0000000069483785
|
|
996
|
|
|
‡2
PTBNP|1446696
|
|
996
|
|
|
‡2
ISNI|0000000431310183
|
|
996
|
|
|
‡2
DNB|1229418873
|
|
996
|
|
|
‡2
PTBNP|1449545
|
|
996
|
|
|
‡2
SUDOC|234315687
|
|
996
|
|
|
‡2
NII|DA03751848
|
|
996
|
|
|
‡2
RERO|A003239603
|
|
996
|
|
|
‡2
ISNI|0000000069223481
|
|
996
|
|
|
‡2
PTBNP|1901600
|
|
996
|
|
|
‡2
LC|n 2003077536
|
|
996
|
|
|
‡2
PTBNP|1015201
|
|
996
|
|
|
‡2
ISNI|000000007050319X
|
|
996
|
|
|
‡2
LC|nb2023011615
|
|
996
|
|
|
‡2
ISNI|0000000391814052
|
|
996
|
|
|
‡2
ARBABN|000070992
|
|
996
|
|
|
‡2
BNCHL|10000000000000000796616
|
|
996
|
|
|
‡2
PTBNP|1842663
|
|
996
|
|
|
‡2
DNB|1211412199
|
|
996
|
|
|
‡2
PTBNP|1238306
|
|
996
|
|
|
‡2
PTBNP|1543597
|
|
996
|
|
|
‡2
PTBNP|285957
|
|
996
|
|
|
‡2
BNF|16699695
|
|
996
|
|
|
‡2
BIBSYS|90352462
|
|
996
|
|
|
‡2
SUDOC|223564028
|
|
996
|
|
|
‡2
LC|n 83207090
|
|
996
|
|
|
‡2
LC|nb2008016429
|
|
996
|
|
|
‡2
PTBNP|1335077
|
|
996
|
|
|
‡2
LC|no2014164016
|
|
996
|
|
|
‡2
RERO|A027397206
|
|
996
|
|
|
‡2
PTBNP|1595034
|
|
996
|
|
|
‡2
SUDOC|071523960
|
|
996
|
|
|
‡2
SUDOC|15807775X
|
|
996
|
|
|
‡2
PTBNP|1349840
|
|
996
|
|
|
‡2
LC|no2022071373
|
|
996
|
|
|
‡2
BLBNB|000394188
|
|
996
|
|
|
‡2
ISNI|0000000070312019
|
|
996
|
|
|
‡2
ISNI|0000000079953867
|
|
996
|
|
|
‡2
ISNI|0000000069587912
|
|
996
|
|
|
‡2
PTBNP|1368995
|
|
996
|
|
|
‡2
PTBNP|1796986
|
|
996
|
|
|
‡2
BAV|495_80526
|
|
996
|
|
|
‡2
BIBSYS|13063775
|
|
996
|
|
|
‡2
ISNI|0000000070107437
|
|
996
|
|
|
‡2
LC|n 86116262
|
|
996
|
|
|
‡2
BNF|17120535
|
|
996
|
|
|
‡2
NUKAT|n 2013008787
|
|
996
|
|
|
‡2
J9U|987007322243705171
|
|
996
|
|
|
‡2
BLBNB|000301578
|
|
996
|
|
|
‡2
ISNI|0000000067764794
|
|
996
|
|
|
‡2
BLBNB|000252609
|
|
996
|
|
|
‡2
DNB|1236530217
|
|
996
|
|
|
‡2
RERO|A000006465
|
|
996
|
|
|
‡2
PTBNP|1472452
|
|
996
|
|
|
‡2
J9U|987007440074405171
|
|
996
|
|
|
‡2
LC|n 2019251989
|
|
996
|
|
|
‡2
PTBNP|951436
|
|
996
|
|
|
‡2
PTBNP|948208
|
|
996
|
|
|
‡2
SUDOC|111314070
|
|
996
|
|
|
‡2
DNB|1051729831
|
|
996
|
|
|
‡2
PTBNP|1353072
|
|
996
|
|
|
‡2
BNCHL|10000000000000000198487
|
|
996
|
|
|
‡2
BNCHL|10000000000000000077108
|
|
996
|
|
|
‡2
ISNI|0000000053563588
|
|
996
|
|
|
‡2
ISNI|0000000069079002
|
|
996
|
|
|
‡2
PTBNP|1195921
|
|
996
|
|
|
‡2
ISNI|0000000071854303
|
|
996
|
|
|
‡2
NTA|382829611
|
|
996
|
|
|
‡2
ISNI|0000000070319704
|
|
996
|
|
|
‡2
ISNI|0000000069527856
|
|
996
|
|
|
‡2
PTBNP|32534
|
|
996
|
|
|
‡2
ISNI|0000000428219274
|
|
996
|
|
|
‡2
SUDOC|24378015X
|
|
996
|
|
|
‡2
SUDOC|195563387
|
|
996
|
|
|
‡2
SUDOC|085900370
|
|
996
|
|
|
‡2
PTBNP|1890225
|
|
996
|
|
|
‡2
PTBNP|907496
|
|
996
|
|
|
‡2
ISNI|0000000067466922
|
|
996
|
|
|
‡2
PTBNP|1476330
|
|
996
|
|
|
‡2
ISNI|0000000070737375
|
|
996
|
|
|
‡2
ISNI|0000000428241455
|
|
996
|
|
|
‡2
NII|DA17571254
|
|
996
|
|
|
‡2
ISNI|0000000029219584
|
|
996
|
|
|
‡2
SUDOC|225790025
|
|
996
|
|
|
‡2
PTBNP|1684680
|
|
996
|
|
|
‡2
LC|n 2007205691
|
|
996
|
|
|
‡2
LC|n 89132786
|
|
996
|
|
|
‡2
NUKAT|n 2017168517
|
|
996
|
|
|
‡2
BNF|17983217
|
|
996
|
|
|
‡2
J9U|987012472862805171
|
|
996
|
|
|
‡2
NSK|000528006
|
|
996
|
|
|
‡2
ISNI|0000000070934010
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
